Navigation Links
Unigene Provides 2012 Business Outlook
Date:1/9/2012

program
  • Continue to build a robust portfolio of feasibility programs with various pharmaceutical companies evaluating Unigene's industry-leading Peptelligence™ platform for oral delivery of proprietary peptides across a broad spectrum of therapeutic areas
  • Convert at least one Peptelligence™ feasibility study into a definitive license agreement associated with significant milestones and royalties
  • File an IND and begin Phase 1 clinical testing of Unigene's lead metabolic peptide, UGP281, targeting patients with morbid obesity
  • Select lead molecule for Type 2 diabetes indication under joint development vehicle (JDV) with Nordic Bioscience
  • Announce preclinical results for Type 2 diabetes indication under JDV with Nordic Bioscience
  • Palmer continued, "We have established Unigene as the oral peptide delivery innovator and partner-of-choice, and we are now ideally positioned to capitalize on the numerous opportunities our industry leading oral peptide delivery platform can realize in 2012.  In addition, we intend to secure a superb development and commercialization partner for our oral PTH program, a high-value asset with the potential to provide a more compliant and patient friendly therapy for the estimated 75 million osteoporosis sufferers worldwide."

    Palmer concluded, "Prospects for the successful turnaround and long-term future of Unigene have never been brighter or more realizable.  Given this cautious optimism and confidence, all members of Unigene's senior management team and I, along with our Board of Directors, have chosen to increase our personal investments in Unigene, to demonstrate our strong commitment to the Company and our belief in our ability to execute our targeted growth strategy in 2012."

    Unigene Therapeutics Outlook

    Unigene is focused on advancing its own pipeline of novel, proprietary peptide product candidates focused on metabolic disease
    '/>"/>

    SOURCE Unigene Laboratories, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
    2. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
    3. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
    4. Unigene Reports Third Quarter 2011 Financial Results
    5. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
    6. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
    7. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
    8. VIVUS Provides Qnexa Regulatory Update
    9. New Product Planning Excellence Services Program Provides Road Map for Clinical Development Success in the Pharmaceutical Industry
    10. ViroPharma Provides 2012 Outlook
    11. Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
    (Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
    (Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
    Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
    ... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
    ... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
    Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
    (Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
    (Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
    (Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
    (Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and related ... evening dresses . All the company’s old and new ... is up to 66 percent off. , SweetDressy.com ... field. Its dress specialists are striving to make more ... the world. All the company’s items are unique, graceful ...
    (Date:10/19/2014)... causes inflammation in the spinal joints and was ... Egyptian royal families. Now a new study published ... of the American College of Rheumatology (ACR), refutes ... called diffuse idiopathic skeletal hyperostosis (DISH) in royal ... Dynasties. , Ankylosing spondylitis is a member ...
    Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
    ... The National Alliance on Mental Illness (NAMI) reminds ... Health Awareness Month, a time for public education about serious ... 2008, the U.S. House of Representatives designated July as Bebe ... of the leading African American novelist and journalist, who also ...
    ... Va., July 1 Christian Children,s Fund, one ... now ChildFund International. The new name takes effect today. ... the organization,s new strategy to meet the needs of children ... and helps 15.2 million children and family members in 31 ...
    ... 21 criminal convictions secured , , INDIANAPOLIS, July 1 ... its Fraud and Abuse department, working with its ... 2008 as a result of its anti-fraud efforts. These efforts ... agencies. , , This announcement comes the day ...
    ... a micro-thin shield against acid attack -- , ... L. Moore, MD, wants women to know that their dental ... Crest and Oral-B Pro-Health products because they offer preventive solutions ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090701/NY38331 ...
    ... Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) ... U.S. / Canada Dial-in Number: 866.272.9941, ... Code: 45596036, Replay Dial-in Number: 888.286.8010, ...
    ... Kids watching food commercials consumed 45 percent more snacks, study ... ads on TV leads to a boost in snacking among ... researchers say. , Yale University researchers conducted a series of ... One test found that children aged 7 to 11 who ...
    Cached Medicine News:Health News:NAMI Observes Minority Mental Health Awareness Month 2Health News:Christian Children's Fund Name Change to ChildFund International Official 2Health News:WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008 2Health News:WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008 3Health News:Dr. Donnica Moore Advocates that Women Follow a Preventive Dental Health Routine that Includes Crest Pro-Health Enamel Shield 2Health News:Dr. Donnica Moore Advocates that Women Follow a Preventive Dental Health Routine that Includes Crest Pro-Health Enamel Shield 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:TV Ads Trigger Mindless Eating 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: